Results 111 to 120 of about 418,264 (199)

Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N). [PDF]

Cancer Chemother Pharmacol
Iimura Y, Iihara H, Aoyama T, Hayashi T, Ishibashi M, Sasuga C, Furukawa N, Anzai E, Ijichi Y, Kuroda S.   +9 more
europepmc   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

Patient-Reported Symptom Changes Following Structured Intake Advice for Multivitamin-Associated Nausea After Bariatric Surgery. [PDF]

Cureus
Kruizinga I, Pereira A, Smelt H.
europepmc   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source

Moving beyond promethazine: Advancing precision in antiemetic therapy. [PDF]

SAGE Open Med
Ryan MF, Lagasse C.
europepmc   +1 more source

Gabapentinoids‐duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting

British Journal of Clinical Pharmacology, EarlyView.
Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili, Maurizio Evangelista, Elena Lucarini, Elena G. Giugliano, Carla Ghelardini, Laura Micheli, Lorenzo Di Cesare Mannelli   +6 more
wiley   +1 more source

Persistent nausea burden at peak antiemetic therapy in palliative care: an exploratory study. [PDF]

BMC Palliat Care
Pietsch P, Summerer L, Mair R, Müller K, Authier D, Herr W, Rechenmacher M, Schnell A.   +7 more
europepmc   +1 more source

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar, Daniela Gorski, Marcela Harumi Kagueiama, Astrid Wiens   +3 more
wiley   +1 more source

Incidence and Risk Factors of Chemotherapy-Induced Nausea and Vomiting Among Adult Cancer Patients at Mbarara Regional Referral Hospital: A Prospective Study. [PDF]

Clin Pharmacol
Muasya PK, Yadesa TM, Isiiko J, Kyomya J, Oenga J, Amina A, Nimusiima G, Joel S, Tumwebaza JM, Makuza KR.   +9 more
europepmc   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source